TY - JOUR
T1 - CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease
AU - Noguchi-Shinohara, Moeko
AU - Tokuda, Takahiko
AU - Yoshita, Mitsuhiro
AU - Kasai, Takashi
AU - Ono, Kenjiro
AU - Nakagawa, Masanori
AU - El-Agnaf, Omar M.A.
AU - Yamada, Masahito
N1 - Funding Information:
The laboratory of O.M.E. is supported by FMHS and UAE University (Al Ain, UAE), Michael J. Fox Foundation for Parkinson's Research (NY), Parkinson's Disease Foundation (NY) and Terry Fox Foundation for Cancer Research (Dubai). This work was supported in part by a grant for the Knowledge Cluster Initiative [High-Tech Sensing and Knowledge Handling Technology (Brain Technology)] (to M.Y.), a grant for the 21st Century COE Program (on Innovative Brain Science for Development, Learning and Memory) (to M.Y.), and Grant-in-Aid for Scientific Research (C) (20591007) (to T.T.), from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan.
PY - 2009/1/28
Y1 - 2009/1/28
N2 - Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.
AB - Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.
KW - Alpha-synuclein
KW - Dementia with Lewy bodies
KW - Parkinson's disease
KW - Parkinsonism
UR - http://www.scopus.com/inward/record.url?scp=58149374375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149374375&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2008.11.055
DO - 10.1016/j.brainres.2008.11.055
M3 - Article
C2 - 19071095
AN - SCOPUS:58149374375
SN - 0006-8993
VL - 1251
SP - 1
EP - 6
JO - Brain Research
JF - Brain Research
ER -